Boston Scientific(US:BSX) Sou Hu Cai Jing·2025-03-29 08:14Group 1 - The core viewpoint of the article highlights the robust growth of China's economy and its medical industry, with Boston Scientific being a key player in this transformation over the past 30 years [1] - Boston Scientific has experienced double-digit growth in China over the past three years, serving over 2.3 million patients and covering nearly 5,000 hospitals in 2024 [1] - The company aims to deepen collaboration across the entire industry chain, focusing on technological innovation to contribute to high-quality development in alignment with China's "Healthy China" goal [1] Group 2 - The new institutional opening-up framework in China, as outlined in the "2025 Action Plan for Stabilizing Foreign Investment," reflects the country's commitment to high-level openness and a stable business environment [4] - Boston Scientific is committed to investing in China, developing a localized strategy that includes establishing self-owned factories and deep collaboration with local partners [4] - The company has achieved full-chain localization in China, integrating clinical application needs with global technological advantages, and utilizing AI and digital technologies to enhance innovation capabilities [4] Group 3 - Boston Scientific believes in the vast potential of the Chinese market and emphasizes the importance of collaboration with local partners to ensure that Chinese innovations benefit global patients [5]